The Pennant Group (PNTG) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
31 Mar, 2026Executive summary
Annual meeting scheduled for May 14, 2026, with voting on three key proposals: election of directors, ratification of Deloitte & Touche LLP as auditor, and advisory approval of executive compensation.
Only shareholders of record as of March 17, 2026, are eligible to vote, with 34,953,297 shares outstanding.
Proxy materials and the 2025 Annual Report are available online, and multiple voting methods are provided.
Voting matters and shareholder proposals
Shareholders will vote on electing three Class I directors for three-year terms, ratifying Deloitte & Touche LLP as auditor for 2026, and approving executive compensation on an advisory basis.
Board recommends voting FOR all proposals.
Quorum requires a majority of outstanding shares; abstentions and broker non-votes count toward quorum but not as votes for proposals.
Shareholder proposals for the 2027 meeting must be submitted between February 13 and March 15, 2027.
Board of directors and corporate governance
Board is classified into three staggered classes, with annual elections for one class.
Current nominees: Christopher R. Christensen, Brent J. Guerisoli, and John G. Nackel, Ph.D.; Christensen and Nackel are independent.
Majority of board members are independent per Nasdaq rules; independent directors meet in executive session annually.
Four standing committees: Audit, Compensation, Nominating and Corporate Governance, and Quality Assurance and Compliance.
Board leadership combines CEO and Chairman roles, with a lead independent director.
Directors receive cash and stock compensation, with annual retainers and automatic restricted stock grants; compensation is benchmarked to peer companies.
Latest events from The Pennant Group
- Record 2025 revenue and EPS growth, with 2026 guidance projecting further double-digit gains.PNTG
Q4 20251 Apr 2026 - Major acquisitions fuel growth, with integration and margin expansion as top priorities.PNTG
Oppenheimer 36th Annual Healthcare MedTech & Services Conference18 Mar 2026 - Expanding in the Southeast, leveraging local leadership, and preparing for regulatory changes.PNTG
Jefferies 2025 Healthcare Services Conference3 Feb 2026 - Q2 revenue up 27.6%, net income doubled, and guidance raised on strong segment growth.PNTG
Q2 20242 Feb 2026 - Q3 revenue up 28.9% to $180.7M, adjusted EPS $0.26, and guidance raised for 2024.PNTG
Q3 202415 Jan 2026 - Leadership-driven growth, payer diversity, and M&A fuel recovery and expansion amid regulatory shifts.PNTG
Stephens 26th Annual Investment Conference | NASH202413 Jan 2026 - Disciplined growth, leadership investment, and tech adoption drive strong outlook for 2025.PNTG
Oppenheimer 35th Annual Health Care MedTech and Services Conference26 Dec 2025 - Record 2024 revenue and net income growth, with double-digit gains expected in 2025.PNTG
Q4 20242 Dec 2025 - Annual meeting to vote on directors, officer exculpation, incentives, auditor, and pay.PNTG
Proxy Filing2 Dec 2025